The combination of a BRAF inhibitor (BRAFi) together with an anti-EGFR inhibitor (EGFRi) represents a standard of care approach in BRAFV600E metastatic colorectal cancer (mCRC) patients. The gene discussed is BRAF; the disease is metastatic colorectal cancer.